INV-1120 is under clinical development by Ionova Life Science and currently in Phase I for Liver Cancer. According to GlobalData, Phase I drugs for Liver Cancer have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how INV-1120’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

INV-1120 overview

INV-1120 is under development for the treatment of cancer, solid tumors including colorectal, breast, pancreatic, lung cancer, sarcoma and liver cancers. It is administered orally. It acts by targeting EP4.

Ionova Life Science overview

Ionova Life Science (Ionova) is a clinical-stage biotechnology company. The company focuses on drug development for oncology and other cancer medicinal targets. Its drug product portfolio includes INV-1120, an immuno-oncology molecule for solid tumors. The company service offering includes preclinical research, clinical trials, drug development, drug discovery programs, research and development. It operates research and development centres and offices in Hong Kong and the US. Ionova is headquartered in Shenzhen, Guangdong, China.

For a complete picture of INV-1120’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.